Literature DB >> 12812992

Agonist- and antagonist-induced sequestration/internalization of neuropeptide Y Y1 receptors in HEK293 cells.

Leng Hong Pheng1, Yvan Dumont, Alain Fournier, Jean-Guy Chabot, Alain Beaudet, Rémi Quirion.   

Abstract

1 Neuropeptide Y Y(1) receptors are known to internalize following the binding of agonists. In the present study, a pseudopeptide Y(1) receptor antagonist, homodimeric Ile-Glu-Pro-Dpr-Tyr-Arg-Leu-Arg-Tyr-CONH(2) (GR231118), also induced Y(1) receptor internalization in human embryonic kidney (HEK293) cells. 2 We demonstrated first that both specifically bound radiolabeled antagonist ([(125)I]GR231118) and agonist ([(125)I][Leu(31), Pro(34)]PYY) underwent receptor-mediated sequestration/internalization in transfected HEK293 cells. 3 Agonist-induced Y(1) receptor internalization was dependent on clathrin-coated pits and was regulated in part by Gi/o-protein activation as revealed by pertussin toxin sensitivity. In contrast, antagonist-induced sequestration of Y(1) receptors was partly dependent on clathrin-coated pits, but independent from Gi/o-protein activation. 4 Exposure to high concentrations of agonist or antagonist caused a 50 and 75% loss of cell surface binding, respectively. The loss caused by the agonist rapidly recovered. This phenomenon was blocked by monensin, an inhibitor of endosome acidification, suggesting that cell surface receptor recovery is due to recycling. In contrast to the agonist, GR231118 induced a long-lasting sequestration of Y(1) receptors in HEK293 cells. 5 Immunofluorescence labeling indicated that following 40 min of incubation with either the agonist or the antagonist, Y(1) receptors followed markedly different intercellular trafficking pathways. 6 Taken together, these findings provided evidence that a pseudopeptide Y(1) receptor antagonist can induce long-lasting disappearance of cell surface receptors through a pathway distinct from the classical endocytic/recycling pathway followed by stimulation with an agonist.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12812992      PMCID: PMC1573902          DOI: 10.1038/sj.bjp.0705306

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

1.  GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonists.

Authors:  E M Parker; C K Babij; A Balasubramaniam; R E Burrier; M Guzzi; F Hamud; G Mukhopadhyay; M S Rudinski; Z Tao; M Tice; L Xia; D E Mullins; B G Salisbury
Journal:  Eur J Pharmacol       Date:  1998-05-15       Impact factor: 4.432

2.  Distribution of a novel hypothalamic neuropeptide Y receptor gene and it's absence in rat.

Authors:  A Burkhoff; D L Linemeyer; J A Salon
Journal:  Brain Res Mol Brain Res       Date:  1998-01

3.  Expression of the neuropeptide Y Y1 receptor in human embryonic kidney 293 cells: ligand binding characteristics, in situ hybridization and receptor autoradiography.

Authors:  Y Tong; Y Dumont; S H Shen; H Herzog; J Shine; R Quirion
Journal:  Brain Res Mol Brain Res       Date:  1995-12-28

Review 4.  BIBP 3226, the first selective neuropeptide Y1 receptor antagonist: a review of its pharmacological properties.

Authors:  H N Doods; H A Wieland; W Engel; W Eberlein; K D Willim; M Entzeroth; W Wienen; K Rudolf
Journal:  Regul Pept       Date:  1996-08-27

Review 5.  XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors.

Authors:  M C Michel; A Beck-Sickinger; H Cox; H N Doods; H Herzog; D Larhammar; R Quirion; T Schwartz; T Westfall
Journal:  Pharmacol Rev       Date:  1998-03       Impact factor: 25.468

6.  Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor.

Authors:  B F Roettger; D Ghanekar; R Rao; C Toledo; J Yingling; D Pinon; L J Miller
Journal:  Mol Pharmacol       Date:  1997-03       Impact factor: 4.436

Review 7.  Regulatory mechanisms that modulate signalling by G-protein-coupled receptors.

Authors:  S K Böhm; E F Grady; N W Bunnett
Journal:  Biochem J       Date:  1997-02-15       Impact factor: 3.857

8.  Differential internalization of somatostatin in COS-7 cells transfected with SST1 and SST2 receptor subtypes: a confocal microscopic study using novel fluorescent somatostatin derivatives.

Authors:  D Nouel; G Gaudriault; M Houle; T Reisine; J P Vincent; J Mazella; A Beaudet
Journal:  Endocrinology       Date:  1997-01       Impact factor: 4.736

9.  Pharmacological evaluation of 1229U91, a novel high-affinity and selective neuropeptide Y-Y1 receptor antagonist.

Authors:  S S Hegde; D W Bonhaus; W Stanley; R M Eglen; T M Moy; M Loeb; S G Shetty; A DeSouza; J Krstenansky
Journal:  J Pharmacol Exp Ther       Date:  1995-12       Impact factor: 4.030

10.  Synthesis and characterization of a selective peptide antagonist of neuropeptide Y vascular postsynaptic receptors.

Authors:  M J Lew; R Murphy; J A Angus
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

View more
  14 in total

1.  BODIPY-conjugated neuropeptide Y ligands: new fluorescent tools to tag Y1, Y2, Y4 and Y5 receptor subtypes.

Authors:  Yvan Dumont; Pierrette Gaudreau; Manuela Mazzuferi; Daniel Langlois; Jean-Guy Chabot; Alain Fournier; Michele Simonato; Rémi Quirion
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

2.  Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.

Authors:  Mihaela Ginj; Hanwen Zhang; Beatrice Waser; Renzo Cescato; Damian Wild; Xuejuan Wang; Judit Erchegyi; Jean Rivier; Helmut R Mäcke; Jean Claude Reubi
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-20       Impact factor: 11.205

3.  Tumor Targeting and Pharmacokinetics of a Near-Infrared Fluorescent-Labeled δ-Opioid Receptor Antagonist Agent, Dmt-Tic-Cy5.

Authors:  Amanda Shanks Huynh; Veronica Estrella; Valerie E Stark; Allison S Cohen; Tingan Chen; Todd J Casagni; Jatinder S Josan; Mark C Lloyd; Joseph Johnson; Jongphil Kim; Victor J Hruby; Josef Vagner; David L Morse
Journal:  Mol Pharm       Date:  2016-01-08       Impact factor: 4.939

4.  Internalization of the human nicotinic acid receptor GPR109A is regulated by G(i), GRK2, and arrestin3.

Authors:  Guo Li; Ying Shi; Haishan Huang; Yaping Zhang; Kuangpei Wu; Jiansong Luo; Yi Sun; Jianxin Lu; Jeffrey L Benovic; Naiming Zhou
Journal:  J Biol Chem       Date:  2010-05-11       Impact factor: 5.157

5.  Quantitative analysis of neuropeptide Y receptor association with beta-arrestin2 measured by bimolecular fluorescence complementation.

Authors:  L E Kilpatrick; S J Briddon; S J Hill; N D Holliday
Journal:  Br J Pharmacol       Date:  2010-04-28       Impact factor: 8.739

Review 6.  Neuropeptide Y overexpression using recombinant adeno-associated viral vectors.

Authors:  Francesco Noé; Angelisa Frasca; Claudia Balducci; Mirjana Carli; Gunther Sperk; Francesco Ferraguti; Asla Pitkänen; Ross Bland; Helen Fitzsimons; Matthew During; Annamaria Vezzani
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

7.  Functional characterization of human variants of the mu-opioid receptor gene.

Authors:  Ajay Ravindranathan; Geoff Joslyn; Margaret Robertson; Marc A Schuckit; Jennifer L Whistler; Raymond L White
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-15       Impact factor: 11.205

8.  Juxtacellular recording/labeling analysis of physiological and anatomical characteristics of rat intergeniculate leaflet neurons.

Authors:  Stephen Thankachan; Benjamin Rusak
Journal:  J Neurosci       Date:  2005-10-05       Impact factor: 6.709

9.  Illuminating the life of GPCRs.

Authors:  Ilka Böhme; Annette G Beck-Sickinger
Journal:  Cell Commun Signal       Date:  2009-07-14       Impact factor: 5.712

Review 10.  Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection.

Authors:  Michael M Lederman; Robin Jump; Heather A Pilch-Cooper; Michael Root; Scott F Sieg
Journal:  Retrovirology       Date:  2008-12-18       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.